If you took NIH funding and got a drug approved by the FDA in the last 3 years, you are part of an elite group of 4 small-cap publicly-traded biotech names ranging in size from $13 Million to $6.8 Billion[1].
Why does this matter? Because 3 out of these 4 companies have seen their shares soar 330%[2]. We think the fourth biotech company – Opiant …View the full post at: They Developed A Disruptive Drug With Government Funding And Trade Crazy Cheap …
Related Articles:
Now Is The Time To Invest In The Electric Car Boom
Enbridge Snubs Canada By Investing $2 Billion in U.S. Pipeline Project
Actinium Pharmaceuticals: Another Promising Name In The AML Space
Barrick Gold Plans Huge Asset Sale
